Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

The oncologist - 1 Jan 2011

Deenen Maarten J, Cats Annemieke, Beijnen Jos H, Schellens Jan H M

Abstract excerpt

Response to treatment with anticancer drugs is subject to wide interindividual variability. This variability is expressed not only as differences in severity and type of toxicity, but also as differences in effectiveness. Variability in the constitution of genes involved in the pharmacokinetic and pharmacodynamic pathways of anticancer drugs has been shown to possibly translate into differences in treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to EGFR gene
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to Neoplasms

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 21659612
DOI: 10.1634/theoncologist.2010-0261
PMCID: PMC3228142

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.PMID 21659612Read ↗

Part 1: background, methodology, and clinical adoption of pharmacogenetics.Semantic proximity Read ↗

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.Semantic proximity Read ↗

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.Semantic proximity Read ↗

Pharmacogenetics and pharmacogenomics of anticancer agents.Semantic proximity Read ↗

Pharmacogenetics in cancer chemotherapy: balancing toxicity and response.Semantic proximity Read ↗

Cancer pharmacogenomics: implications on ethnic diversity and drug response.Semantic proximity Read ↗

Pharmacogenomics in cancer therapy: is host genome variability important?Semantic proximity Read ↗

Using genetic variation to optimize cancer chemotherapy.Semantic proximity Read ↗

Pharmacogenetics of Drugs Used in the Treatment of CancersSemantic proximity Read ↗

Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical ImplicationsSemantic proximity Read ↗

Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.Semantic proximity Read ↗

Cancer pharmacogeneticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.